Currently, there are 39.11M common shares owned by the public and among those 30.40M shares have been available to trade.
The company’s stock has a 5-day price change of 45.41% and -3.06% over the past three months. HOWL shares are trading -26.17% year to date (YTD), with the 12-month market performance up to 41.79% higher. It has a 12-month low price of $1.57 and touched a high of $8.19 over the same period. HOWL has an average intraday trading volume of 160.79K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 39.36%, 34.29%, and -30.48% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Werewolf Therapeutics Inc (NASDAQ: HOWL) shares accounts for 58.53% of the company’s 39.11M shares outstanding.
It has a market capitalization of $124.54M and a beta (3y monthly) value of 0.46. The earnings-per-share (ttm) stands at -$1.35. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.04% over the week and 7.70% over the month.
Earnings per share for the fiscal year are expected to decrease by -53.81%, and -19.09% over the next financial year. EPS should grow at an annualized rate of 10.90% over the next five years, compared to -13.31% over the past 5-year period.
Looking at the support for the HOWL, a number of firms have released research notes about the stock. JMP Securities stated their Mkt Outperform rating for the stock in a research note on April 03, 2024, with the firm’s price target at $12. Wedbush coverage for the Werewolf Therapeutics Inc (HOWL) stock in a research note released on August 24, 2023 offered a Outperform rating with a price target of $9. Jefferies was of a view on June 06, 2023 that the stock is Buy, while BofA Securities gave the stock Buy rating on September 10, 2021, issuing a price target of $26. SVB Leerink on their part issued Outperform rating on May 25, 2021.
